LEADER 01724nam 2200385z- 450 001 9910694418603321 005 20080621090138.0 035 $a(CKB)5860000000019969 035 $a(BIP)022730096 035 $a(EXLCZ)995860000000019969 100 $a20220406c2007uuuu -u- - 101 0 $aeng 200 10$aContinuation of 9/11 health effects $eenvironmental impacts for residents and responders : hearing before the Subcommittee on Government Management, Organization, and Procurement of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Tenth Congress, first session, April 23, 2007 215 $a1 online resource (iii, 127 p.) 311 $a0-16-080950-9 517 $aContinuation of 9/11 health effects 606 $aSeptember 11 Terrorist Attacks, 2001$xHealth aspects$zNew York (State)$zNew York 606 $aSeptember 11 Terrorist Attacks, 2001$xEnvironmental aspects$zNew York (State)$zNew York 606 $aVictims of terrorism$xMedical care$zNew York (State)$zNew York 606 $aVictims of terrorism$xServices for$zNew York (State)$zNew York 607 $aBrooklyn (New York, N.Y.)$xEnvironmental conditions 610 $aSeptember 11 terrorist attacks, 2001 610 $aVictims of terrorism 610 $aUnited States 610 $aHistory 610 $aPolitical science 610 $aScience 615 0$aSeptember 11 Terrorist Attacks, 2001$xHealth aspects 615 0$aSeptember 11 Terrorist Attacks, 2001$xEnvironmental aspects 615 0$aVictims of terrorism$xMedical care 615 0$aVictims of terrorism$xServices for 906 $aBOOK 912 $a9910694418603321 996 $aContinuation of 9$93201536 997 $aUNINA LEADER 04740nam 2200613z- 450 001 9910163538103321 005 20210211 035 $a(CKB)3710000001048138 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/49986 035 $a(oapen)doab49986 035 $a(EXLCZ)993710000001048138 100 $a20202102d2016 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aImmunogenic Cell Death in Cancer: From Benchside Research to Bedside 210 $cFrontiers Media SA$d2016 215 $a1 online resource (145 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88919-838-3 330 $aClassically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated 'danger signaling' remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and 'danger signaling' has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of "immunogenic cell death" (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality. 517 $aImmunogenic Cell Death in Cancer 606 $aCell Death 606 $aApoptosis 606 $aMonitoring, Immunologic 606 $aGenes, Tumor Suppressor 606 $aImmunogenic Cell Death 606 $aNeoplasms 610 $aanti-tumor immunity 610 $aApoptosis 610 $acancer immunology 610 $acancer immunotherapy 610 $aCell Death 610 $aDAMPs 610 $adanger signals 610 $aimmunocontexture 610 $aimmunosurveillance 610 $anecroptosis 610 $apatient immunology 610 $aprognostic/predictive biomarker 615 2$aCell Death. 615 2$aApoptosis. 615 2$aMonitoring, Immunologic. 615 2$aGenes, Tumor Suppressor. 615 2$aImmunogenic Cell Death. 615 2$aNeoplasms. 700 $aAbhishek D. Garg$4auth$01331951 702 $aPatrizia Agostinis$4auth 906 $aBOOK 912 $a9910163538103321 996 $aImmunogenic Cell Death in Cancer: From Benchside Research to Bedside$93040695 997 $aUNINA